acapatamab + AMG 404

**Acapatamab + AMG 404** is an investigational combination therapy studied primarily for metastatic castration-resistant prostate cancer (mCRPC). **Acapatamab** (AMG 160) is a half-life extended bispecific T-cell engager (BiTE) that targets prostate-specific membrane antigen (PSMA) on tumor cells and CD3 on T cells, promoting immune-mediated killing of prostate cancer cells. **AMG 404** is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as a checkpoint inhibitor to enhance T-cell anti-tumor activities. This combination aims to leverage direct T-cell-mediated cytotoxicity against PSMA-positive tumor cells (acapatamab) while overcoming checkpoint-mediated immunosuppression (AMG 404). Early-phase clinical trials have demonstrated manageable safety profiles, notable cytokine release syndrome, and preliminary anti-tumor activity, but no approvals as of now[2][3][5][7].